Synergetic photoimmunotherapy with dual-inhibition of EZH2/Akt | Synapse
February 28, 2026
Synergetic photoimmunotherapy with dual-inhibition of EZH2/Akt
Key Points
The research aims to explore the effectiveness of dual inhibition of EZH2 and Akt in enhancing photoimmunotherapy for tumor treatment.
Utilized a multifunctional nanoplatform for photothermal therapy and immune sensitization.
Combined dual inhibition of EZH2 and Akt as a strategy for therapy.
Applied advanced techniques to assess anti-tumor efficacy.
Significant enhancement in anti-tumor effects observed with the dual inhibition.
Increased immune response was correlated with the use of the nanoplatform.
Abstract
The nanoplatform of B-Nb 2 O 5– x @DA@E/A provides a multifunctional sensitization strategy for anti-tumor therapy through photothermal therapy combined with immune response.